OBIO Orchestra BioMed Holdings, Inc.
USHealthcareAs of 2026-07-10 16:00
Why OBIO matters now
Orchestra BioMed Holdings, Inc. (OBIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.99 with +1.79% on the session and $238.9M in market capitalization; recent performance reads 1-month -0.25% and YTD -3.86%.
The latest financial table shown here is Q1 2026, with revenue of $110.0K, net income of $-20.7M, and EPS of $-0.54. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -23.1%.
The latest indexable market news headline is "Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.00; recent insider activity includes Hochman David P filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.01
P/S
7.30
EV/EBITDA
-4.63
DCF Value
$-6.71
FCF Yield
-23.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.3%
Operating Margin
-168.0%
Net Margin
-167.0%
ROE
-138.0%
ROA
-54.3%
ROIC
-62.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $110.0K | $-20.7M | $-0.54 |
| Q4 2025 | $30.9M | $6.2M | $0.16 |
| FY 2025 | $33.5M | $-52.7M | $-1.38 |
| Q3 2025 | $861.0K | $-20.8M | $-0.54 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.00
Target (Median)
$13.00
Target Range
$13.00 - $13.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.50
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.